Yeast Cells Encapsulating Polymer Nanoparticles as Trojan Particles via in Situ Polymerization inside Cells

Integrated oral microgel system ameliorates renal fibrosis by hitchhiking co-delivery and targeted gut flora modulation

BACKGROUND

Renal fibrosis is a progressive process associated with chronic kidney disease (CKD), contributing to impaired kidney function. Active constituents in traditional Chinese herbs, such as emodin (EMO) and asiatic acid (AA), exhibit potent anti-fibrotic properties. However, the oral administration of EMO and AA results in low bioavailability and limited kidney accumulation. Additionally, while oral probiotics have been accepted for CKD treatment through gut microbiota modulation, a significant challenge lies in ensuring their viability upon administration. Therefore, our study aims to address both renal fibrosis and gut microbiota imbalance through innovative co-delivery strategies.

RESULTS

In this study, we developed yeast cell wall particles (YCWPs) encapsulating EMO and AA self-assembled nanoparticles (NPYs) and embedded them, along with Lactobacillus casei Zhang, in chitosan/sodium alginate (CS/SA) microgels. The developed microgels showed significant controlled release properties for the loaded NPYs and prolonged the retention time of Lactobacillus casei Zhang (L. casei Zhang) in the intestine. Furthermore, in vivo biodistribution showed that the microgel-carried NPYs significantly accumulated in the obstructed kidneys of rats, thereby substantially increasing the accumulation of EMO and AA in the impaired kidneys. More importantly, through hitchhiking delivery based on yeast cell wall and positive modulation of gut microbiota, our microgels with this synergistic strategy of therapeutic and modulatory interactions could regulate the TGF-β/Smad signaling pathway and thus effectively ameliorate renal fibrosis in unilateral ureteral obstruction (UUO) rats.

CONCLUSION

In conclusion, our work provides a new strategy for the treatment of renal fibrosis based on hitchhiking co-delivery of nanodrugs and probiotics to achieve synergistic effects of disease treatment and targeted gut flora modulation.

Microbial nanotechnology for agriculture, food, and environmental sustainability: Current status and future perspective

The field of nanotechnology has the mysterious capacity to reform every subject it touches. Nanotechnology advancements have already altered a variety of scientific and industrial fields. Nanoparticles (NPs) with sizes ranging from 1 to 100 nm (nm) are of great scientific and commercial interest. Their functions and characteristics differ significantly from those of bulk metal. Commercial quantities of NPs are synthesized using chemical or physical methods. The use of the physical and chemical approaches remained popular for many years; however, the recognition of their hazardous effects on human well-being and conditions influenced serious world perspectives for the researchers. There is a growing need in this field for simple, non-toxic, clean, and environmentally safe nanoparticle production methods to reduce environmental impact and waste and increase energy productivity. Microbial nanotechnology is relatively a new field. Using various microorganisms, a wide range of nanoparticles with well-defined chemical composition, morphology, and size have been synthesized, and their applications in a wide range of cutting-edge technological areas have been investigated. Green synthesis of the nanoparticles is cost-efficient and requires low maintenance. The present review highlights the synthesis of the nanoparticles by different microbes, their characterization, and their biotechnological potential. It further deals with the applications in biomedical, food, and textile industries as well as its role in biosensing, waste recycling, and biofuel production.

Fabrication of high-performance cell-imprinted polymers based on AuNPs/MXene composites via metal-free visible light-induced ATRP

Cell-imprinted polymers (CIPs) for yeasts were fabricated via metal-free visible-light-induced atom transfer radical polymerization (MVL ATRP) on the surface of a glassy carbon electrode (GCE) which had been modified with gold nanoparticles (AuNPs)/MXene (Ti₃C₂T_x) composites. Here, the AuNPs/Ti₃C₂T_x composites form a macroporous structure, which could improve the electron transfer rate of the materials and facilitate the leaving or rebinding of cells. Methacrylic acid (MAA) and N,N'-methylene bis-acrylamide (MBA) were selected as the functional monomer and cross-linker of CIPs, because they could form efficient hydrogen bonding with mannan from yeast cell walls. The obtained electrode (CIPs/AuNPs/Ti₃C₂T_x/GCE) was characterized by electrochemical impedance spectroscopy (EIS), scanning electron microscopy (SEM), and X-ray photoelectron spectroscopy (XPS). Further experiments indicated that the CIPs/AuNPs/Ti₃C₂T_x/GCE electrode could be utilized as an electrochemical biosensor to determine yeast cells by differential pulse voltammetry (DPV). The linear response range was 1.0 × 10² to 1.0 × 10⁹ cells per mL and the detection limit was 20 cells per mL (S/N = 3). The CIPs/AuNPs/Ti₃C₂T_x/GCE electrode also showed good selectivity, repeatability, reproducibility, and regeneration. Finally, the proposed sensor was used to detect yeast cells in commercial samples of Saccharomyces boulardii sachets by a standard addition method. The obtained recovery was from 96.9 to 104.8% showing its potential applications in clinical and diagnostic research.

Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects

Iron oxide nanoparticle (IONPs) have become a subject of interest in various biomedical fields due to their magnetism and biocompatibility. They can be utilized as heat mediators in magnetic hyperthermia (MHT) or as contrast media in magnetic resonance imaging (MRI), and ultrasound (US). In addition, their high drug-loading capacity enabled them to be therapeutic agent transporters for malignancy treatment. Hence, smartening them allows for an intelligent controlled drug release (CDR) and targeted drug delivery (TDD). Smart magnetic nanoparticles (SMNPs) can overcome the impediments faced by classical chemo-treatment strategies, since they can be navigated and release drug via external or internal stimuli. Recently, they have been synchronized with other modalities, e.g., MRI, MHT, US, and for dual/multimodal theranostic applications in a single platform. Herein, we provide an overview of the attributes of MNPs for cancer theranostic application, fabrication procedures, surface coatings, targeting approaches, and recent advancement of SMNPs. Even though MNPs feature numerous privileges over chemotherapy agents, obstacles remain in clinical usage. This review in particular covers the clinical predicaments faced by SMNPs and future research scopes in the field of SMNPs for cancer theranostics.

Encapsulation of wild oregano, Plectranthus amboinicus (Lour.) Spreng, phenolic extract in baker's yeast for the postharvest control of anthracnose in papaya

BACKGROUND

Anthracnose caused by Colletotrichum gloeosporioides is considered as a major postharvest disease affecting many fruits. This plant disease is traditionally managed with synthetic fungicides, which are generally toxic and are linked to pathogen resistance. Recently, microencapsulated bioactives have been developed as potential alternative strategies to these methods, while utilizing natural fungicides and other phytochemicals. Wild oregano, Plectranthus amboinicus (Lour.) Spreng, contains potent antimicrobial phenolics, but these compounds are volatile and relatively unstable, which limits their efficacy during application. Herein, a baker's yeast microencapsulation system was applied to improve the stability of wild oregano phenolic extract (WOPE) and enhance its antifungal activity against anthracnose.

RESULTS

Encapsulation of WOPE in plasmolyzed yeast cells afforded a high encapsulation efficiency (93%) and yielded WOPE-loaded yeast microcapsules (WLYMs) with an average diameter of 2.65 μm. Storage stability studies showed WLYMs are stable for at least 4 months. A 24  -h in vitro release experiment showed that WLYMs had an initial burst release upon redispersion in water, followed by a controlled release to about 80% of the loaded WOPE. Upon application as a spray-type postharvest treatment for papaya, WLYMs exhibited a significantly improved mycelial inhibitory action against C. gloeosporioides and greatly reduced the anthracnose symptoms in papaya fruits.

CONCLUSION

This study presented a yeast microencapsulation system that can effectively stabilize WOPE and enhance its antifungal activity, making this microparticle formulation a promising environmentally safe postharvest treatment option to combat anthracnose symptoms in papaya fruits. © 2022 Society of Chemical Industry.

Yeast Cells in Microencapsulation. General Features and Controlling Factors of the Encapsulation Process

Besides their best-known uses in the food and fermentation industry, yeasts have also found application as microcapsules. In the encapsulation process, exogenous and most typically hydrophobic compounds diffuse and end up being passively entrapped in the cell body, and can be released upon application of appropriate stimuli. Yeast cells can be employed either living or dead, intact, permeabilized, or even emptied of all their original cytoplasmic contents. The main selling points of this set of encapsulation technologies, which to date has predominantly targeted food and-to a lesser extent-pharmaceutical applications, are the low cost, biodegradability and biocompatibility of the capsules, coupled to their sustainable origin (e.g., spent yeast from brewing). This review aims to provide a broad overview of the different kinds of yeast-based microcapsules and of the main physico-chemical characteristics that control the encapsulation process and its efficiency.

Entrapping of Nanoparticles in Yeast Cell Wall Microparticles for Macrophage-Targeted Oral Delivery of Cabazitaxel

In this work, a nano-in-micro carrier was constructed by loading polymer-lipid hybrid nanoparticles (NPs) into porous and hollow yeast cell wall microparticles (YPs) for macrophage-targeted oral delivery of cabazitaxel (CTX). The YPs, primarily composed of natural β-1,3-d-glucan, can be recognized by the apical membrane receptor, dectin-1, which has a high expression on macrophages and intestinal M cells. By combining electrostatic force-driven self-deposition with solvent hydration/lyophilization methods, the positively charged NPs loaded with CTX or fluorescence probes were efficiently packaged into YPs, as verified by scanning electron microscope (SEM), atomic force mircoscope (AFM), and confocal laser scanning microscopy (CLSM) images. NP-loaded YPs (NYPs) showed a slower in vitro drug release and higher drug stability compared with NPs in a simulated gastrointestinal environment. Biodistribution experiments confirmed a widespread distribution and extended retention time of NYPs in the intestinal tract after oral administration. Importantly, a large amount of NYPs were primarily accumulated and transported in the intestinal Peyer's patches as visualized in distribution and absorption site studies, implying that NYPs were mainly absorbed through the lymphatic pathway. In vitro cell evaluation further demonstrated that NYPs were rapidly and efficiently taken up by macrophages via receptor dectin-1-mediated endocytosis using a mouse macrophage RAW 264.7 cell line. As expected, in the study of in vivo pharmacokinetics, the oral bioavailability of CTX was improved to 32.1% when loaded in NYPs, which is approximately 5.7 times higher than that of the CTX solution, indicating the NYPs are efficient for oral targeted delivery. Hence, this nano-in-micro carrier is believed to become a hopeful alternative strategy for increasing the oral absorption of small molecule drugs.

Vacuum facilitated infusion of bioactives into yeast microcarriers: Evaluation of a novel encapsulation approach

Encapsulation into yeast microcarriers provides an appealing alternative to biomimetic systems by employing natural, pre-formed vehicles for the stabilization and delivery of bioactives compounds. However, current (diffusion-limited) methods of encapsulation using yeast require long time scales and heating which lead to poor encapsulation efficiencies and yields. This study evaluates the usage of vacuum infusion to encapsulate two model bioactives, curcumin and fisetin, into yeast and yeast cell wall particles and the physical parameters, e.g. vacuum level, concentration of carrier solvent, log p value of bioactive, etc., which facilitate the process of vacuum infusion. Encapsulation efficiencies were determined using UV-vis spectrophotometry. Localization of bioactives within yeast microcarriers was determined using confocal and multiphoton (two-photon) microscopy. 99% vacuum, or 1.0kPa, and 35% ethanol (v/v) provide the optimal conditions for the encapsulation of both curcumin and fisetin; compared to the diffusion-limited method, vacuum infusion is able to encapsulate 3× more curcumin and 2× more fisetin into yeast microcarrier and requires 288-fold less time. Enhanced encapsulation efficiencies and yield as well as rapid encapsulation process technology presented in this study can transform the use of cell based carriers for encapsulation and delivery of bioactives.